Search Results 471-480 of 16621 for alopecia

1. A Study to Evaluate CC-98633 to Treat Subjects with Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Agree to refrain ...

2. Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy - Mayo Clinic

   Toxicities related to all prior anticancer therapies must have resolved or stabilized, apart from alopecia and peripheral neuropathy. Note: Peripheral ...

3. A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia - Mayo Clinic

   Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy. History of non-compliance to medical regimens. Participating Mayo Clinic ...

4. Office of Postdoctoral Affairs and Research Training - Programs

   Mayo Clinic Office of Postdoctoral Affairs and Research Training: Support and advocacy for the professional and academic needs of Mayo's research trainees.

5. Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer that has been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) - Mayo Clinic

   ... alopecia and the criteria outlined; Patients must not have any history of cancer within 5 years from randomization, with the exception of in-situ carcinomas ...

6. INCB161734 for Advanced or Metastatic Solid Tumors With KRAS G12D Mutation - Mayo Clinic

   ... alopecia) are exceptions and may enroll. For participants in Parts 2a and 2b who will be receiving retifanlimab as part of this study: immune-related ...

7. Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC) - Mayo Clinic

   Participants with type 1 diabetes, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible; ...

8. Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy - Mayo Clinic

   ... alopecia, anemia and any signs or symptoms of androgen deprivation therapy); Willing to provide tissue and blood samples for correlative research purposes ...

9. A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors - Mayo Clinic

   0) due to prior cancer therapy (subjects with alopecia may be enrolled). Has a history or current evidence of any condition, therapy, or laboratory ...

10. A Study to Evaluate Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol) - Mayo Clinic

    Acute effects of any prior therapy resolved to baseline severity or to Common Terminology Criteria for Adverse Events (CTCAE) grade ≤ 1 (except for alopecia, ...